Plasma serine protease inhibitors in patients with liver cirrhosis
Piatkowska, M.; Kotschy, M.; Rość, D.; Wiśniewska, E.; Opoka, J.
Acta Haematologica Polonica 25(2): 145-149
1994
ISSN/ISBN: 0001-5814 PMID: 8067185 Document Number: 437863
In 28 patients with liver cirrhosis as compared with the control group decreased concentrations of alpha 2-antiplasmin, antithrombin III and activator plasminogen inhibitor were observed. Decrease of these inhibitors was lower in advanced stages of cirrhosis accompanied by hypoalbuminemia and hyperbilirubinemia.
Document emailed within 1 workday
Related Documents
Swiatkowski, M.; Pulkowski, G.; Kłopocka, M.; Budzyński, J.; Wiśniewsk, E.; Kotschy, M. 2001: Serine protease inhibitors in plasma of patients with ulcerative colitis Przeglad Lekarski 58(2): 67-70Kłoczko, J.; Bielawiec, M.; Galar, M.; Czaczkowska, T.; Wojtukiewicz, M. 1991: Protein C and plasma serine protease inhibitors in patients with essential hypertension Polski Tygodnik Lekarski 46(50-52): 974-976
Liu, J.; Wang, H.-Y.; Li, J.-Y. 2008: Advances in researches on epididymal WFDC-type serine protease inhibitors Zhonghua Nan Ke Xue 14(11): 1027-1030
Hudig, D.; Allison, N.J.; Pickett, T.M.; Winkler, U.; Kam, C.M.; Powers, J.C. 1991: The function of lymphocyte proteases. Inhibition and restoration of granule-mediated lysis with isocoumarin serine protease inhibitors Journal of Immunology 147(4): 1360-1368
Hashimoto, E.; Takeuchi, F.; Yamamura, H. 1990: Protease-activated form of protein kinase C with Mr 80,000 generated from rat liver plasma membrane by trypsin-like protease Biochemistry International 21(5): 949-957
Derkx, F.H.; Bouma, B.N.; Schalekamp, M.A. 1984: Prorenin-renin conversion by the contact activation system in human plasma: role of plasma protease inhibitors Journal of Laboratory and Clinical Medicine 103(4): 560-573
Macías, J.; Mira, J.é A.; López-Cortés, L.F.; Santos, I.; Girón-González, J.é A.; González-Serrano, M.; Merino, D.; Hernández-Quero, J.é; Rivero, A.; Merchante, N.ás.; Trastoy, M.ón.; Carrillo-Gómez, R.; Arizcorreta-Yarza, A.; Gómez-Mateos, J.ús.; Pineda, J.A. 2006: Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C Antiviral Therapy 11(7): 839-846
Sakai, J. 2001: Site-1 protease: a subtilisin-like serine protease that cleaves SREBPs for controlling the lipid biosynthesis in animal cell Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 2): 277-282
Ku, G.S.; Quigley, J.P.; Sultzer, B.M. 1983: The inhibition of the mitogenic stimulation of B lymphocytes by a serine protease inhibitor: commitment to proliferation correlates with an enhanced expression of a cell-associated arginine-specific serine enzyme Journal of Immunology 131(5): 2494-2499
Leonhardt, H.; Bungert, H.J. 1974: Investigations on plasma viscosity in patients with cirrhosis of the liver Acta Hepato-Gastroenterologica 21(2): 127-130
Bianchi, G.; Marchesini, G.; Fabbri, A.; Ronchi, M.; Chianese, R.; Grossi, G. 1997: Lipoperoxide plasma levels in patients with liver cirrhosis Hepato-Gastroenterology 44(15): 784-788
Ghosh, P. 1989: The role of serine proteinases and serine proteinase inhibitors in the pathobiology of connective tissues Nihon Seikeigeka Gakkai Zasshi 63(5): 643-652
Ruan, P.; Gong, Z-Jiong.; Zhang, Q-Rong. 2004: Changes of plasma D(-)-lactate, diamine oxidase and endotoxin in patients with liver cirrhosis Hepatobiliary and Pancreatic Diseases International: Hbpd Int 3(1): 58-61
Hilgeroth, A.; Langner, A. 2000: Plasma protein binding properties of dimeric 4-aryl-1,4-dihydropyridines as novel non peptidic HIV-1 protease inhibitors Die Pharmazie 55(7): 542-543
Gragnoli, G.; Tanganelli, I.; Signorini, A.M. 1980: Behavior of plasma insulin, C-peptide and glucagon in normal subjects and in patients with liver cirrhosis Bollettino della Societa Italiana di Biologia Sperimentale 56(1): 69-75
Kunde, K. 2000: HIV therapy: toxic liver injuries caused by protease inhibitors? Deutsche Medizinische Wochenschrift 125(12): A12-A13
Baltzer, G. 1973: Hemodynamics in liver cirrhosis. Hemodynamic peculiarities and possibility of their modification by vasoactive agents in patients with liver cirrhosis Fortschritte der Medizin 91(6): 253-257
Cercek, L.; Cercek, B. 1993: Cancer-associated SCM-recognition, immunedefense suppression, and serine protease protection peptide. Part III. CRISPP peptide protection of serine proteases against inhibition Cancer Detection and Prevention 17(3): 447-454
Choi, J.-y.; Kwon, O.-K.; Choi, S.Y.; Park, Y.K.; Kim, S.S. 2011: Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 50(1): 19-25
Saito, N.; Kaji, H.; Hisamura, M.; Murao, M. 1983: Plasma levels of monocarboxylic short chain fatty acids in patients with diabetes mellitus, liver cirrhosis and thyroidal dysfunction Research Communications in Chemical Pathology and Pharmacology 39(2): 337-340